Literature DB >> 33658920

D-4F Ameliorates Contrast Media-Induced Oxidative Injuries in Endothelial Cells via the AMPK/PKC Pathway.

Yansong Guo1, Wei Li2, Mingming Qian2, Ting Jiang3, Ping Guo2, Qian Du2, Na Lin1, Xianwei Xie1, Zhiyong Wu1, Donghai Lin3, Donghui Liu1,2.   

Abstract

Endothelial dysfunction is involved in the pathophysiological processes of contrast media (CM)-induced acute kidney injury (CI-AKI) after vascular angiography or intervention. Previous study found that apolipoprotein A-I (apoA-I) mimetic peptide, D-4F, alleviates endothelial impairments via upregulating heme oxygenase-1 (HO-1) expression and scavenging excessively generated reactive oxygen species (ROS). However, whether D-4F could ameliorate oxidative injuries in endothelial cells through suppressing ROS production remains unclear. In this study, a representative nonionic iodinated CM, iodixanol, was chosen for the in vitro and in vivo studies. Endothelial cell viability was assayed using micrographs, lactate dehydrogenase (LDH) activity, and cell counting kit-8 (CCK-8). Apoptosis was detected using flow cytometry analysis and caspase-3 activation. Endothelial inflammation was tested using monocyte adhesion assay and adhesion molecule expression. ROS production was detected by measuring the formation of lipid peroxidation malondialdehyde (MDA) through the thiobarbituric acid reactive substance (TBARS) assay. Peroxynitrite (ONOO⁻) formation was tested using the 3-nitrotyrosine ELISA kit. Iodixanol impaired cell viability, promoted vascular cell adhesion molecule-1 (VCAM-1) and intercellular cell adhesion molecule-1 (ICAM-1) expression, and induced cell apoptosis in human umbilical vein endothelial cells (HUVECs). However, D-4F mitigated these injuries. Furthermore, iodixanol induced the phosphorylation of protein kinase C (PKC) beta II, p47, Rac1, and endothelial nitric oxide synthase (eNOS) at Thr495, which elicited ROS release and ONOO⁻ generation. D-4F inhibited NADPH oxidase (NOX) activation, ROS production, and ONOO⁻ formation via the AMP-activated protein kinase (AMPK)/PKC pathway. Additionally, after an intravascular injection of iodixanol in Sprague Dawley rats, iodixanol induced a remarkable inflammatory response in arterial endothelial cells, although significant apoptosis and morphological changes were not observed. D-4F alleviated the vessel inflammation resulting from iodixanol in vivo. Collectively, besides scavenging ROS, D-4F could also suppress ROS production and ONOO⁻ formation through the AMPK/PKC pathway, which ameliorated oxidative injuries in endothelial cells. Hence, D-4F might serve as a potential agent in preventing CI-AKI.
Copyright © 2021 Guo, Li, Qian, Jiang, Guo, Du, Lin, Xie, Wu, Lin and Liu.

Entities:  

Keywords:  apolipoprotein A-I mimetic peptide; contrast media; endothelial cell; high-density lipoprotein; oxidative stress

Year:  2021        PMID: 33658920      PMCID: PMC7917283          DOI: 10.3389/fphar.2020.556074

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  3 in total

1.  The Acid Sphingomyelinase Inhibitor Amitriptyline Ameliorates TNF-α-Induced Endothelial Dysfunction.

Authors:  Yang Ji; Jing Chen; Lihua Pang; Changnong Chen; Jinhao Ye; Hao Liu; Huanzhen Chen; Songhui Zhang; Shaojun Liu; Benrong Liu; Chuanfang Cheng; Shiming Liu; Yun Zhong
Journal:  Cardiovasc Drugs Ther       Date:  2022-09-14       Impact factor: 3.947

2.  Combined transcriptomic and lipidomic analysis of D-4F ameliorating bleomycin-induced pulmonary fibrosis.

Authors:  Yong Xia; Mei Cheng; Yanyan Hu; Man Li; Lin Shen; Xiang Ji; Xiaopei Cui; Xiangju Liu; Weiling Wang; Haiqing Gao
Journal:  Ann Transl Med       Date:  2021-09

3.  An ApoA-I Mimic Peptide of 4F Promotes SDF-1α Expression in Endothelial Cells Through PI3K/Akt/ERK/HIF-1α Signaling Pathway.

Authors:  Kaixuan Lv; Lingyu Kong; Mei Yang; Linlin Zhang; Shangmin Chu; Lichun Zhang; Jielun Yu; Guoshen Zhong; Yanhua Shi; Xia Wang; Nana Yang
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.